Potentia

Company Overview

Snapshot

Founded in April 2026, Potentia operates with 1–10 employees. The company has raised $90,000 across one funding round from one investor. In May 2026, Potentia secured its seed funding from Peregrine Ventures.

Business overview

Potentia Therapeutics is a biotechnology company focused on developing Antibody-Oligonucleotide Conjugates (AOCs) for targeted RNA therapies, specifically addressing diseases of the Peripheral Nervous System (PNS). The company's core technology involves linking short interfering RNA (siRNA) to target antibodies, enabling direct delivery of RNA-interference therapeutics into peripheral nerve tissues to silence disease-causing genes. Its lead drug candidate is designed to treat Charcot-Marie-Tooth disease 1A (CMT1A) by restoring myelin formation and nerve function. The underlying platform is also applicable to other conditions, including diabetic peripheral neuropathy, chemotherapy-induced neuropathy, and age-related hearing loss, positioning Potentia within the biopharmaceutical, healthcare, and biotechnology sectors.

Company Intelligence Q&A

When was Potentia founded?

Potentia was founded in April 2026.

What is Potentia's primary focus?

Potentia focuses on developing Antibody-Oligonucleotide Conjugates (AOCs) for targeted RNA therapies, particularly for diseases of the Peripheral Nervous System (PNS).

What is Potentia's lead drug candidate targeting?

Potentia's lead drug candidate targets Charcot-Marie-Tooth disease 1A (CMT1A) to restore myelin formation and nerve function.

Which investor participated in Potentia's funding round?

In May 2026, Potentia secured $90,000 in seed funding from Peregrine Ventures.

What is the total capital raised by Potentia?

Potentia has raised a total of $90,000 across one funding round.